Tagged with S

Saudi Arabia In a recent conversation with PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey, CEO of the Saudi Food and Drug Authority (SFDA) outlined the organisation’s strategic priorities. As part of the Authority’s 2018-2022 strategic plan, it has set out a number of goals, ranging from setting clearer objectives to strengthening its capabilities,…

Switzerland hystrix medical is an online contracting marketplace for medical devices and replenishing/repeat purchase products in hospitals. CEO Philippe Hügli explains the company’s origins and model today, his ambitions beyond the company’s home market of Switzerland, and why a digital sales approach is core to “360-degree customer centricity.”   The consumer…

Switzerland Biotech veteran Brian O’Callaghan introduces ObsEva – a Swiss-based firm focused on women’s health –, his motivations to join the company – which is on the verge of transforming into a commercial-stage outfit –, and the strategy he has put in place moving forward. O’Callaghan also shares his insights on…

Latvia Dr Valters Bolevics, director general of the Association of International Research-based Pharmaceuticals Manufacturers of Latvia (SIFFA), outlines the progress made on market access for innovative pharmaceuticals in Latvia in recent years and the hurdles still to be overcome to catch up with its Baltic neighbours.   Stable pharmaceutical product market…

Saudi Arabia Speaking exclusively to PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey, CEO of the Saudi Food and Drug Authority (SFDA), outlines the SFDA’s key priorities under its current strategic plan. He also touches on why domestic pharma and medtech manufacturing is important to the SFDA, pricing issues for innovative new therapies, and…

Switzerland In a wide-ranging interview CEO Bertrand Ducrey introduces Debiopharm’s unique business focus on drug improvement, drug delivery, and drug targeting; recent progress in oncology, including an FDA breakthrough designation and out-licensing deal for its head and neck cancer product; as well as a host of other topics, including the company’s…

Canada Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease drugs could look like.   On January 27, 2021, Health Canada launched a consultation on the development of a National…

Mexico Last Wednesday, the lower chamber of the Mexican Congress approved a bill that would legalise recreational marijuana. With a population of nearly 130 million people, Mexico would join Canada and Uruguay as the only countries to legalise marijuana at the national level in the continent and it would become the…

Global From almost being de-listed by the NASDAQ stock index in 2018 due to poor financial performance, US vaccine firm Novavax has completed a remarkable turnaround. Now the holder of one of the world’s leading COVID-19 vaccine candidates and the recipient of billions of dollars in funding from the US government…

Brazil Founded in 1950, EMS is one of the top two domestic pharma companies in Brazil. As a key player in the largest and most populous nation in Latin America, the company has around 13 percent of the Brazilian market share with gross sales of USD 2.5 billion in 2019.  …

Americas Writing in the March edition of DIA’s Global Forum magazine, EMD Serono’s Ana Padua outlines the findings of a recent study into accelerated regulatory pathways in Latin America which aim to reduce approval timelines for innovative medicines.   The Latin America region offers a number of registration pathways to accelerate…

Global The global rush to secure access to COVID-19 vaccines has led to accusations that richer countries are hoarding supply at the expense of poorer nations. While some are calling for a relaxation of intellectual property (IP) to allow less-developed nations to vaccinate their populations, Big Pharma is resistant, arguing that…